Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. https://doi.org/10.1089/thy.2015.0020.

Article  PubMed  PubMed Central  Google Scholar 

Sherma SI. Thyroid carcinoma. The Lancet. 2003;361(9356):501–11. https://doi.org/10.1016/S0140-6736(03)12488-9.

Article  Google Scholar 

Pacini F, Fuhrer D, Elisei R, et al. ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur Thyroid J. 2022;11(1). https://doi.org/10.1530/ETJ-21-0046.

Rosário PW, Ward LS, Carvalho GA, et al. Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensus. Arq Bras Endocrinol Metabol. 2013;57(4):240–64. https://doi.org/10.1590/S0004-27302013000400002.

Article  PubMed  Google Scholar 

Tuttle RM, Tala H, Shah J, et al. Estimating Risk of Recurrence in Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation: Using Response to Therapy Variables to Modify the Initial Risk Estimates Predicted by the New American Thyroid Association Staging System. Thyroid. 2010;20(12):1341–9. https://doi.org/10.1089/thy.2010.0178.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ballal S, Soundararajan R, Garg A, Chopra S, Bal C. Intermediate-risk differentiated thyroid carcinoma patients who were surgically ablated do not need adjuvant radioiodine therapy: long-term outcome study. Clin Endocrinol (Oxf). 2016;84(3):408–16. https://doi.org/10.1111/cen.12779.

Article  CAS  PubMed  Google Scholar 

Tuttle RM, Sabra MM. Selective use of RAI for ablation and adjuvant therapy after total thyroidectomy for differentiated thyroid cancer: A practical approach to clinical decision making. Oral Oncol. 2013;49(7):676–83. https://doi.org/10.1016/j.oraloncology.2013.03.444.

Article  PubMed  Google Scholar 

Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA. Adjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid Cancer. J Clin Endocrinol Metab. 2015;100(4):1529–36. https://doi.org/10.1210/jc.2014-4332.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim SK, Woo JW, Lee JH, et al. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma. Endocr Relat Cancer. 2016;23(5):367–76. https://doi.org/10.1530/ERC-15-0572.

Article  CAS  PubMed  Google Scholar 

Padovani RDP, Chablani SV, Tuttle RM. Radioactive iodine therapy: multiple faces of the same polyhedron. Arch Endocrinol Metab. Published online May 13, 2022. https://doi.org/10.20945/2359-3997000000461.

Zafon C, Díez JJ, Galofré JC, Cooper DS. Nodular Thyroid Disease and Thyroid Cancer in the Era of Precision Medicine. Eur Thyroid J. 2017;6(2):65–74. https://doi.org/10.1159/000457793.

Article  PubMed  PubMed Central  Google Scholar 

Liu J, Zhang Z, Huang H, et al. Total thyroidectomy versus lobectomy for intermediate-risk papillary thyroid carcinoma: A single-institution matched-pair analysis. Oral Oncol. 2019;90:17–22. https://doi.org/10.1016/j.oraloncology.2019.01.010.

Article  PubMed  Google Scholar 

Xu S, Huang H, Huang Y, et al. Comparison of Lobectomy vs Total Thyroidectomy for Intermediate-Risk Papillary Thyroid Carcinoma With Lymph Node Metastasis. JAMA Surg. 2023;158(1):73. https://doi.org/10.1001/jamasurg.2022.5781.

Article  PubMed  Google Scholar 

Adam MA, Pura J, Gu L, et al. Extent of Surgery for Papillary Thyroid Cancer Is Not Associated With Survival: An Analysis of 61,775 Patients. Ann Surg. 2014;260(4):601–7. https://doi.org/10.1097/SLA.0000000000000925.

Article  PubMed  Google Scholar 

Chen W, Li J, Peng S, et al. Association of Total Thyroidectomy or Thyroid Lobectomy With the Quality of Life in Patients With Differentiated Thyroid Cancer With Low to Intermediate Risk of Recurrence. JAMA Surg. 2022;157(3):200. https://doi.org/10.1001/jamasurg.2021.6442.

Article  PubMed  Google Scholar 

Park S, Kim WG, Song E, et al. Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy. Thyroid. 2017;27(4):524–30. https://doi.org/10.1089/thy.2016.0477.

Article  CAS  PubMed  Google Scholar 

Momesso DP, Vaisman F, Yang SP, et al. Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine. J Clin Endocrinol Metab. 2016;101(7):2692–700. https://doi.org/10.1210/jc.2015-4290.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vaisman F, Shaha A, Fish S, Michael TR. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin Endocrinol (Oxf). 2011;75(1):112–9. https://doi.org/10.1111/j.1365-2265.2011.04002.x.

Article  CAS  PubMed  Google Scholar 

Colombo C, De Leo S, Di Stefano M, et al. Total Thyroidectomy Versus Lobectomy for Thyroid Cancer: Single-Center Data and Literature Review. Ann Surg Oncol. 2021;28(8):4334–44. https://doi.org/10.1245/s10434-020-09481-8.

Article  PubMed  PubMed Central  Google Scholar 

Dobrinja C, Samardzic N, Giudici F, et al. Hemithyroidectomy versus total thyroidectomy in the intermediate-risk differentiated thyroid cancer: the Italian Societies of Endocrine Surgeons and Surgical Oncology Multicentric Study. Updat Surg. 2021;73(5):1909–21. https://doi.org/10.1007/s13304-021-01140-1.

Article  CAS  Google Scholar 

Hartl DM, Guerlain J, Breuskin I, et al. Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer. Cancers. 2020;12(11):3282. https://doi.org/10.3390/cancers12113282.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vuong HG, Altibi AMA, Duong UNP, Hassell L. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma—A meta-analysis. Clin Endocrinol (Oxf). 2017;87(5):411–7. https://doi.org/10.1111/cen.13413.

Article  CAS  PubMed  Google Scholar 

Ronen O, Robbins KT, Olsen KD, et al. Case for staged thyroidectomy. Head Neck. 2020;42(10):3061–71. https://doi.org/10.1002/hed.26393.

Article  PubMed  Google Scholar 

Ibrahim B, Forest VI, Hier M, Mlynarek AM, Caglar D, Payne RJ. Completion thyroidectomy: predicting bilateral disease. J Otolaryngol - Head Neck Surg. 2015;44(1):23. https://doi.org/10.1186/s40463-015-0076-4.

Article  PubMed  PubMed Central  Google Scholar 

Michels JJ, Jacques M, Henry-Amar M, Bardet S. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Hum Pathol. 2007;38(2):212–9. https://doi.org/10.1016/j.humpath.2006.08.001.

Article  PubMed  Google Scholar 

Shaha AR. Extrathyroidal extension—what does it mean. Oral Oncol. 2017;68:50–2. https://doi.org/10.1016/j.oraloncology.2017.03.008.

Article  PubMed  Google Scholar 

Tam S, Amit M, Boonsripitayanon M, et al. Effect of Tumor Size and Minimal Extrathyroidal Extension in Patients with Differentiated Thyroid Cancer. Thyroid. 2018;28(8):982–90. https://doi.org/10.1089/thy.2017.0513.

Article  CAS  PubMed  Google Scholar 

Almeida MFOD, Couto JS, Ticly ALT, et al. The impact of minimal extrathyroidal extension in the recurrence of papillary thyroid cancer patients. Arch Endocrinol Metab. 2020;64(3):251–6. https://doi.org/10.20945/2359-3997000000245.

Article  PubMed  PubMed Central  Google Scholar 

Craig SJ, Bysice AM, Nakoneshny SC, Pasieka JL, Chandarana SP. The Identification of Intraoperative Risk Factors Can Reduce, but Not Exclude, the Need for Completion Thyroidectomy in Low-Risk Papillary Thyroid Cancer Patients. Thyroid. 2020;30(2):222–8. https://doi.org/10.1089/thy.2019.0274.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nicholson KJ, Teng CY, McCoy KL, Carty SE, Yip L. Completion thyroidectomy: A risky undertaking? Am J Surg. 2019;218(4):695–9. https://doi.org/10.1016/j.amjsurg.2019.07.014.

Article  PubMed  Google Scholar 

Gulcelik MA, Dogan L, Akgul GG, Güven EH, Ersöz GN. Completion Thyroidectomy: Safer than Thought. Oncol Res Treat. 2018;41(6):386–90. https://doi.org/10.1159/000487083.

Article  PubMed  Google Scholar 

Van Nostrand D. Selected Controversies of Radioiodine Imaging and Therapy in Differentiated Thyroid Cancer. Endocrinol Metab Clin North Am. 2017;46(3):783–93. https://doi.org/10.1016/j.ecl.2017.04.007.

Article  PubMed  Google Scholar 

Mallick U, Harmer C, Yap B, et al. Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer. N Engl J Med. 2012;366(18):1674–85. https://doi.org/10.1056/NEJMoa1109589.

Article  CAS  PubMed  Google Scholar 

Castagna MG, Cevenini G, Theodoropoulou A, et al. Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. Eur J Endocrinol. 2013;169(1):23–9. https://doi.org/10.1530/EJE-12-0954.

Article  CAS  PubMed  Google Scholar 

Du P, Jiao X, Zhou Y, et al. Low versus high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a meta-analysis of randomized controlled trials. Endocrine. 2015;48(1):96–105. https://doi.org/10.1007/s12020-014-0333-8.

Article  CAS